Boehringer Ingelheim secures FDA accelerated approval for Hernexeos (zongertinib), an oral tyrosine kinase inhibitor targeting HER2 mutations in advanced...

Tevogen Bio Holdings (Nasdaq: TVGN) has announced a significant surge in institutional ownership, with a 60% increase reported between...

Syndax Pharmaceuticals, a commercial-stage oncology company, recently granted stock options to seven new employees. While seemingly a routine event,...

Cosmos Health’s $300 million foray into Ethereum signals a bold, if unconventional, move for the global healthcare group. The...

Full Alliance Group, through its subsidiary Qubitera Holdings, is developing Quant Blockchain, a platform designed to facilitate interoperability between...

Longeviti Neuro Solutions Secures $10 Million and Appoints Seasoned MedTech Leader as Board Chair Longeviti Neuro Solutions, a developer...

Processa Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation cancer therapies, has announced its exploration of cryptocurrency treasury strategies to...

Full Alliance Group’s subsidiary, Qubitera Holdings, is developing Quant Blockchain, a platform designed to facilitate interoperability between healthcare systems,...

Annovis Bio has solidified its intellectual property (IP) portfolio for its lead drug candidate, buntanetap, covering both the original...

VTV Therapeutics has initiated its Phase 3 CATT1 trial, evaluating cadisegliatin as an oral adjunctive therapy to insulin for...